AG
ZYNE

Algert Global’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Algert Global’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,873
Closed -$57K – 1343
2021
Q4 		$57K Sell
19,873
-15,213
-43% -$56.3K 0.01% 934
2021
Q3 		$149K Buy
35,086
+9,368
+36% +$41.8K 0.02% 945
2021
Q2 		$136K Buy
25,718
+4,940
+24% +$23.7K 0.05% 381
2021
Q1 		$97K Hold
20,778
– – 0.03% 413
2020
Q4 		$69K Sell
20,778
-30,250
-59% -$115K 0.02% 390
2020
Q3 		$169K Buy
51,028
+9,880
+24% +$36.3K 0.05% 331
2020
Q2 		$139K Buy
41,148
+9,142
+29% +$43.2K 0.05% 358
2020
Q1 		$123K Buy
+32,006
New +$149K 0.05% 344

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Algert Global's ZYNE Position: Q1 2022 in Review

Algert Global sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 19,873 shares — an estimated $57K sold.

Algert Global first reported a position in ZYNE in Q1 2020 and held it in 8 quarters. The position peaked at $169K in Q3 2020. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • Algert Global reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • Algert Global sold 19,873 Zynerba Pharmaceuticals, Inc shares in Q1 2022, an estimated $57K.
  • Algert Global first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2020 and held it in 8 quarters.
  • Algert Global's Zynerba Pharmaceuticals, Inc position peaked at $169K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Algert Global's 13F filing for Q1 2022, filed 16 May 2022.